Information Provided By:
Fly News Breaks for June 27, 2019
VRCA
Jun 27, 2019 | 08:22 EDT
Verrica Pharmaceuticals last night announced positive Phase 2 results for VP-102 in common warts, a "large underserved" indication impacting 22M Americans, Jefferies analyst David Steinberg tells investors in a research note. The analyst believes that if successfully developed, VP-102 could reach the market in the second half of 2022 as Verrica's second major indication after molluscum. He keeps a Buy rating on the shares with a $24 price target.
News For VRCA From the Last 2 Days
There are no results for your query VRCA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.